SYR-322/CPH-002 Metabolism SYR-322-014 Mass balance -Multi-dose Study SYR-322-101 Bioequivalence† - Single dose Study SYR-322-027 Commercial formulation Food effect Study SYR-322-026 25 mg dose Study SYR-322/CPH-006 SYR-322-CPH-007 Study SYR-322-005 PK in special populations Target Single dose None population§ -Multi-dose Study SYR-322-002 Target population PK Hepatic Study SYR-322-023 Hepatic impairment impairment Renal impairment Study SYR-322-006 Renal impairment None children/ adolescents Elderly Study SYR-322-022 General PK Study SYR-322/CPH-003 General PK Genetic/ gender-related PK Males versus SYR-322-022 General PK females PK interactions MET, cimetidine Study SYR-322-005 Interaction caffeine, Study SYR-322-015 Interaction tolbutamide, dextromethorphan, midazolam, fexofenadine
SYR-322/CPH-002 Metabolism SYR-322-014 Mass balance -Multi-dose Study SYR-322-101 Bioequivalence† - Single dose Study SYR-322-027 Commercial formulation Food effect Study SYR-322-026 25 mg dose Study SYR-322/CPH-006 SYR-322-CPH-007 Study SYR-322-005 PK in special populations Target population§ Single dose None -Multi-dose Study SYR-322-002 Target population PK Hepatic impairment Study SYR-322-023 Hepatic impairment Renal impairment Study SYR-322-006 Renal impairment children/ adolescents None Elderly Study SYR-322-022 General PK Study SYR-322/CPH-003 General PK Genetic/ gender-related PK Males versus females SYR-322-022 General PK PK interactions MET, cimetidine Study SYR-322-005 Interaction caffeine, tolbutamide, dextromethorphan, midazolam, fexofenadine Study SYR-322-015 Interaction
auspar-alogliptin-benzoate-140109-cer.docx